학술논문
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Document Type
Article
Author
Source
In Annals of Oncology June 2019 30(6):970-976
Subject
Language
ISSN
0923-7534